COPENHAGEN, DENMARK, May 26, 2021 /EINPresswire.com/ -- ISD Immunotech (“ISD”), a private biotechnology company developing a novel peptide therapeutic for the treatment of severe systemic lupus erythematosus (SLE), announced today that the US Patent and Trademark Office has granted the company its first US patent covering the lead candidate ISD017. Patent US10,961,279 entitled “Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses” describes novel immunosuppressive domains (ISDs) derived from enveloped RNA viruses including the specific sequence of ISD017, a solubility engineered version of a native isd sequence from influenza virus.